Ankang Li, Ph.D.
Chief Financial Officer
Ankang Li is the Chief Financial Officer of Terns Pharmaceuticals. Dr. Li has a decade of rich experience in investment banking, business development, legal advisory, and biomedical research. Prior to joining Terns, Dr. Li was Executive Director of Asia ex-Japan Healthcare Investment Banking at Goldman Sachs, where he led many high-profile IPOs for biotechnology and other healthcare clients. Before that, Dr. Li was Director at Asia Pacific Innovation Hub of MSD (known as Merck in the U.S. and Canada) overseeing business development and licensing transactions in the region. Dr. Li worked at premium law firms, Davis Polk and Ropes & Gray, before joining MSD, advising clients on capital markets and M&A transactions.
Dr. Li received a Juris Doctor degree from The University of Chicago Law School, a PhD degree in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. Dr. Li conducted postdoctoral research at the Salk Institute. He is a CFA charter holder.